^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Homologous recombination deficiency predicts response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: Secondary analysis of the neocart randomized clinical trial.
Published date:
05/26/2022
Excerpt:
Patients with HRD measurable tumors received DCb in 22 cases and EC-D in 21 cases….Patients in the DCb group who achieved pCR had a higher HRD score (p =0.04), higher stromal TILs (p =0.02), and a higher Ki67 index (p =0.04) than non-pCR patients. RCB 0/1 was associated with higher stromal TILs (P =0.05) and a higher Ki67 index (P =0.008)....PCR in TNBC patients correlated with a higher HRD score, higher stromal TILs, and a higher Ki67 index on carboplatin-based neoadjuvant chemotherapy regardless of BRCA status.
DOI:
10.1200/JCO.2022.40.16_suppl.e12606
Trial ID:
